Results 211 to 220 of about 391,649 (370)

Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?

open access: yesClinical Endocrinology, Volume 103, Issue 2, Page 129-136, August 2025.
ABSTRACT Objective Primary aldosteronism (PA) is the commonest secondary cause of hypertension but case‐detection remains a challenge. Screening is usually performed in secondary care using an aldosterone:renin ratio (ARR) measurement. Here, we describe the outcomes of screening in primary care, in Oxfordshire, UK.
Harsha Anuruddhika Dissanayake   +9 more
wiley   +1 more source

Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4415-4426, August 2025.
Abstract Aims We assessed the effects of dapagliflozin on natriuresis and blood pressure in patients with type 2 diabetes and chronic kidney disease (CKD) and evaluated the consistency of these effects across patients with type 2 diabetes without CKD and CKD without type 2 diabetes.
Jelle M. Beernink   +16 more
wiley   +1 more source

The role of atrial natriuretic peptide (ANP) in chronic liver disease. [PDF]

open access: yes, 1993
Almeida   +82 more
core   +1 more source

Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation

open access: yesEuropean Journal of Clinical Investigation, Volume 55, Issue 8, August 2025.
This consensus highlights critical research gaps in obesity epidemiology, phenotypic heterogeneity and clinical management, calling for advanced methodologies, collaborative strategies and innovative policies to mitigate the global obesity epidemic and its socio‐economic impacts.
Federico Carbone   +28 more
wiley   +1 more source

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV

open access: yesFundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background We aimed to elucidate the role of Angiotensin II type 1 receptor (AT1R) blocker usage in muscle wasting and dysfunction related to HIV. Research Design and Methods Appendicular skeletal muscle mass, higher and lower limb strength, and physical fitness were determined in people living with HIV (PWH) using AT1R blockers users (n = 33),
Rafael Deminice   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy